Abigail Jenkins
Abigail “Abbey” L. Jenkins is an experienced biopharmaceutical executive and board director with more than 25 years of leadership across public and private biotech and pharmaceutical companies. She has a proven track record of building and leading organizations through strategic transformations—including growth, business reshaping, and the pursuit of strategic alternatives—along with commercialization and value creation, having successfully launched six products and raised more than $250 million in capital across her career.
​
Ms. Jenkins is currently the CEO of a Stealth Mode Biotech developing novel therapies for
patients with cancer. She previously served as President, Chief Executive Officer, and a member of the Board of Directors of Gamida Cell, Ltd. (NASDAQ: GMDA), a pioneer in cell therapies for patients with blood cancers. During her tenure, she led the company through the FDA approval and launch of Omisirge®, the first-ever allogeneic hematopoietic stem cell donor source approved in the United States. Prior to Gamida Cell, she was Chief Commercial and Business Officer at Lyndra Therapeutics, where she established and led global commercial, business development, corporate strategy, and portfolio management functions across multiple therapeutic areas.
​
Earlier in her career, Ms. Jenkins served as Chief Commercial and Business Officer at Lyndra Therapeutics, Senior Vice President and Business Unit Head of Vaccines at Emergent BioSolutions (NYSE: EBS), as Chief Commercial Officer and U.S. Business Head at Aquinox Pharmaceuticals (NASDAQ: AQXP). She has also held senior commercial and business development roles at Relypsa, Actavis (now Teva Pharmaceuticals), MedImmune (now AstraZeneca), and Pfizer.
​
Ms. Jenkins currently serves on the Board of Directors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) and previously served on the Board of Directors of XORTX Therapeutics, Inc. (NASDAQ: XRTX). She is also Chair of the Editorial Board of the Biotech CEO Sisterhood. She holds a Master of Science in Biotechnology and Biotechnology Business Enterprise from The Johns Hopkins University, a Bachelor of Arts in Psychology and Biology from Indiana University, and a Certificate of Achievement in General Management as a Kellogg Executive Scholar. In 2022, she was recognized as a PharmaVoice 100 honoree in the Disrupter category, honoring the industry’s most inspiring and impactful leaders.
About the Sisterhood
The Biotech CEO Sisterhood is a vibrant community dedicated to championing the success of women leaders in the biopharma industry. Rooted in a culture of mutual support and authenticity, the Sisterhood aims to inspire and uplift women while driving meaningful conversations and impact across the industry. As part of our commitment to nurturing the current and future generations of biotech leaders, the Sisterhood hosts summits, local events, and educational sessions. These programs encourage dialogue about the challenges facing women in biotech, share best practices, and enhance leadership effectiveness. Since its inception in 2022, the Biotech CEO Sisterhood has grown to 300+ members. To follow our progress and learn more, please follow us on LinkedIn.
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.
​
​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.